BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
BioAge Labs (NASDAQ: BIOA) will present at the 25th Annual Needham Virtual Healthcare Conference April 13–16, 2026. CEO Kristen Fortney will take part in a fireside chat on April 16 from 3:00–3:30 PM EDT.
One-on-one meetings will include CFO Dov Goldstein and CSO BJ Sullivan. A live webcast is available by registration and replays will be archived for 30 days in the investor section of the company's website.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – BIOA
On the day this news was published, BIOA gained 2.35%, reflecting a moderate positive market reaction. Argus tracked a peak move of +16.7% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $16M to the company's valuation, bringing the market cap to $718.51M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
BIOA fell 8.99% while several sector peers in Pharmaceutical Preparations showed gains (e.g., SXTC up 3.57%, IRWD up 1.96%, DERM up 1.76%). Momentum scanner peers were mixed, with CTOR down and ACB and SXTC up, indicating today’s move was more stock-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 27 | Board nominations | Neutral | -0.6% | Nomination Committee proposed board slate and chair re-election for AGM. |
| Mar 24 | Earnings and financing | Positive | -13.5% | Full-year 2025 results, positive BGE-102 Phase 1 data, and follow-on raise. |
| Mar 23 | Clinical data update | Positive | -3.5% | New long-term real-world lecanemab treatment data at AD/PD 2026. |
| Feb 27 | Share count update | Neutral | -0.2% | Update on total shares and votes after stock option program issuance. |
| Feb 19 | Conference presentation | Neutral | +1.8% | Announcement of BIOA presentation at Oppenheimer healthcare conference. |
Recent history shows multiple instances where ostensibly positive or neutral announcements were followed by negative price reactions, especially around data and financial updates.
Over the last few months, BIOA-related news has ranged from conference appearances to major financial and clinical updates. On Mar 24, 2026, full-year 2025 results and positive BGE-102 Phase 1 data coincided with a -13.53% move. A prior conference presentation on Feb 19, 2026 saw a modest +1.84% reaction. Other biotech news items in the feed, including lecanemab data and share-count updates, generally saw small negative moves, underscoring a tendency toward cautious trading around announcements.
Regulatory & Risk Context
An effective Form S-3ASR shelf filed on March 24, 2026 allows BioAge Labs, Inc. to offer common stock, preferred stock, debt securities, warrants, subscription rights, and units in one or more future offerings, with specific terms and amounts to be set in later prospectus supplements.
Market Pulse Summary
This announcement highlights BioAge Labs’ continued participation in major investor conferences, with management appearing in a fireside chat and one-on-one meetings at the Needham Virtual Healthcare Conference from April 13–16, 2026. In context, recent filings show an effective S-3ASR shelf and a strong cash position from 2025 disclosures, alongside net insider selling. Investors may watch upcoming clinical updates and any use of the shelf registration as key future catalysts.
AI-generated analysis. Not financial advice.
EMERYVILLE, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will present at the 25th Annual Needham Virtual Healthcare Conference taking place April 13–16, 2026.
Kristen Fortney, PhD, CEO and co-founder, is scheduled to participate in a fireside chat on Thursday, April 16 from 3:00 PM to 3:30 PM EDT. Kristen Fortney, Dov Goldstein, MD, CFO, and BJ Sullivan, PhD, Chief Strategy Officer, will participate in one-on-one meetings. To access the live webcast of the presentation, register here.
Replays of the webcast will be available in the investor section of the Company's website at https://ir.bioagelabs.com/, and will be archived for 30 days following the presentations.
About BioAge Labs, Inc.
BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The Company's lead product candidate, BGE-102, is a potent, orally available, brain-penetrant small-molecule NLRP3 inhibitor being developed for cardiovascular risk and retinal diseases. A Phase 1 SAD/MAD trial of BGE-102 is underway, with topline data including additional MAD cohorts anticipated in 1H26. The Company is also developing long-acting injectable and oral small molecule APJ agonists for obesity. BioAge’s additional preclinical programs, which leverage insights from the Company’s proprietary discovery platform built on human longevity data, address key pathways involved in metabolic aging.
Contacts
PR: Chris Patil, media@bioagelabs.com
IR: Dov Goldstein, ir@bioagelabs.com
Partnering: partnering@bioagelabs.com
Web: https://bioagelabs.com
